reason report
bottom line yesterday afternoon fda approv
novarti aimovig erenumab anti-cgrp prevent
treatment migrain adult encompass chronic
episod migrain us list price fix one monthli
single-us autoinjector annual label
broad could possibl imagin lack cautionari
warn languag add appeal product profil
believ avoid pitfal excess price
kind high volum indic out-of-pocket cost vari
depend insur statu aimovig co-pay program may abl
help reduc patient out-of-pocket cost littl per month
elig patient commerci insur updat
model chang price probabl success royalti
aimovig well addit biosimilar franchis
revenu line result chang price target increas
previous
first-mov larg market believ
potenti market us patient could benefit anti-cgrp
migrain prevent first new class drug migrain nearli
three decad price drug expect hope
receiv broad patient access coverag price in-lin
botox approv biolog chronic migrain headach
day month prevent would expect similar two-drug
step-edit gener oral aimovig chronic episod
diseas kol call lead approv indic
warehous patient alreadi pass requir
step-edit drug wait first anti-cgrp agent
result believ benefit significantli first mover
advantag ultim retain market share long-term
first expect anti-cgrp approv approv repres
first four expect anti-cgrp antibodi approv come
year expect lilli galcanezumab also approv
see note teva headach mean opportun
aldr migrain rais aldr op surpris
aimovig review europ compani expect approv
come month somewhat inexplic partner
commerci aimovig novarti result enjoy
profit us estim sale
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings p/sale
compani inform leerink partner llc research
revenu million dilut non-gaap ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
profit sale outsid us overal forecast
aimovig achiev sale ultim contribut
total revenu long-term product larg
enough materi grow revenu compani face
multipl biosimilar larg legaci product
annual price lower expect drug list
price per year per monthli inject
expect april institut clinic econom
review icer releas draft evid report valu anti-
cgrp antibodi agenc assum price estim
increment cost-effect anti-cgrp antibodi migrain
determin cost per qualiti adjust life year qali
aimovig chronic migrain episod
migrain standard icer threshold
therefor icer suggest annual price aimovig would need
chronic episod achiev
qali threshold chief rebutt icer analysi
model fail incorpor non-pay cost cost incur employe
employ miss work day
base treatment-experienc patient popul howev amgen
novarti appear less acquiesc icer analysi
set list price near benchmark like
discount icer draft report open public comment
final evid report meet summari anticip
partnership account allow book us sale
receiv ex-u royalti aimovig jointli commerci
novarti agreement term record
us aimovig sale pay novarti signific royalti howev
novarti also share commerci cost ex-u novarti
book sale aimovig pay double-digit royalti
leerink model consensu pt increas
po aimovig increas price per dose
assum discount market model howev
decreas penetr ramp initi year reduc
row share royalti addit also increas
cog associ us sale correct signific royalti
novarti result forecast aimovig sale lower
lower later year current forecast
aimovig sale begin estim us sale
line current us consensu long-term
forecast us sale aimovig
consensu market model base annual net
price aimovig peak us patient treatment number
share model total us patient
treat anti-crgp antibodi simultan model updat
separ broken forecast revenu amgen
biosimilar portfolio recent disclosur meaning
biosimilar sale revenu begin forecast
biosimilar revenu increas
result chang aimovig addit
biosimilar price target increas previous
price target inc stock rate market perform
one first gener pioneer biopharmaceut industri succeed
basi build three massiv revenu pillar legaci product era three
product franchis epo epogen aranesp gcsf neulasta enbrel
face array brand gener competitor mean associ
revenu total like steadili declin offset outlook
number recent develop acquir product growth profit potenti
unlik match legaci brand least mani year manag
respond challeng restructur compani expens base initi dividend
lever compani balanc sheet cash trap off-shore gener make
legaci product compar peer regard defens stock
also one lack explos upsid potenti typic associ breakthrough
price target inc base averag three approach
believ reason basi valu stock today approach simpl price
earn multipl larg cap us eu larg cap biopharma stock azn sni
rhhbi gsk nv celg price sale multipl larg cap biotechnolog
pharma compani novo celg discount cash flow dcf use rel
multipl larg cap biopharma compani ep appli
ep estim give one year futur valu use establish larg
cap futur revenu multipl sale appli revenu forecast
give futur valu final dcf valuat base
current outlook compani exist product probability-weight revenu
contribut late stage pipelin program discount compani
wacc give fair valu today averag three approach give price
target
risk view outlook valuat includ major chang label
price reimburs coverag compani legaci product failur
compani growth portfolio achiev futur sale forecast risk includ develop
delay disappoint earlier stage pipelin asset earlier signific eros
compani legaci product biosimilar innov competit shortfal
compani effort improv oper margin would also materi affect outlook
valuat would larg dilut acquisit therapeut area platform
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
million
corp partner revenue incl royalti
po probabl success fda approv
leerink partner research compani file
million
sale
total expens exclud revenue sharing/incl sg
 total revenu
sg total revenu excl profit share
profit share total revenu
leerink partner research compani file
analysi stock price leerink target
method model larg cap healthcar growth stock ep multipl
ep appli amgen ep
leerink updat ep estim
current averag ep multipl consensu ep
compar slow grow us eu larg cap biopharma
impli target price ep
revenu multipl appli leerink revenu forecast
leerink updat revenu estim
current averag larg cap biopharma multipl revenu
impli valu fy revenu
impli target price ep use us pharma compar
method dcf adjust debt declin flow
stabl termin cash flow growth discount
present valu flow termin valu
averag method
leerink partner research compani file factset
